Cellectar Biosciences, Inc.
Clinical trials sponsored by Cellectar Biosciences, Inc., explained in plain language.
A biopharmaceutical company developing phospholipid-drug conjugates for cancer treatment.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New radiation drug targets brain tumors in kids
Disease control OngoingThis study tests a new drug called CLR 131, a targeted radiotherapy, in children, adolescents, and young adults (ages 10 to 25) with high-grade glioma that has returned or not responded to treatment. The goal is to find the best dose and see if it is safe and can shrink tumors or…
Phase 1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New radioactive drug targets childhood cancers that Won't quit
Disease control OngoingThis early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…
Phase 1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase 2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC